About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research conducted in our group is geared toward elucidating the cause and molecular mechanisms of neurodegeneration in Parkinson's disease (PD), a disabling, currently incurable common neurodegenerative disorder. To this end, we perform clinical and pre-clinical translational research in both PD patients and in human-relevant experimental in vitro and in vivo PD-related models.
Elucidating the molecular mechanisms underlying neurodegeneration in PD should allow to:
PMID: 37075138 Journal: PERFUSION-UK Year: 2023 Reference: Perfusion. 2023 Apr 19:2676591231170480. doi: 10.1177/02676591231170480. Impact factor: Publication type: Paper in international publication Authors: Argudo, Eduard; Barrabes, Jose A; Bonilla, Camilo; Chiscano, Luis; De la Iglesia, Ana; Diaz, Maria Angeles; Ferreira-Gonzalez, Ignacio; Ferrer, Ricard; Font, Marta; Gabaldon, Alejandra et al. DOI: 10.1177/02676591231170480
PMID: 37844866 Journal: NEUROPHARMACOLOGY Year: 2023 Reference: Neuropharmacology. 2023 Oct 14:109759. doi: 10.1016/j.neuropharm.2023.109759. Impact factor: Publication type: Paper in international publication Authors: Benlloch, Luis E; Carcel, Paula; Cedena Romero, Maria Teresa; Crucitti, Davide; De Miguel Sanchez, Carlos; Del Orbe Barreto, Rafael Andres; Diaz Varela, Nicolas A; Diaz-Beya, Marina; Diez-Campelo, Maria; Fernandez-Gonzalez, Pol et al. DOI: 10.1016/j.neuropharm.2023.109759
PMID: 37846799 Journal: CANCER Year: 2023 Reference: Cancer. 2023 Oct 17. doi: 10.1002/cncr.35061. Impact factor: Publication type: Paper in international publication Authors: Bisogno, Gianni; Bouhamama, Amine; Brennan, Bernadette; Brisse, Herve J; Cardoen, Liesbeth; Coma, Ana; Coppadoro, Beatrice; Di Paolo, Pier Luigi; Fayard, Cindy; Fernandez-Gonzalez, Pol et al. DOI: 10.1002/cncr.35061
PMID: 37922009 Journal: INTENSIVE CARE MEDICINE Year: 2023 Reference: Intensive Care Med. 2023 Nov 3. doi: 10.1007/s00134-023-07251-0. Impact factor: Publication type: Editorail in international publication Authors: Ambale-Venkatesh, Bharath; Belohlavek, Jan; Bluemke, David A; Fujii, Tomoki; Gomes, Antoinette S; Hundley, W Gregory; Jung, Christian; Lima, Joao A C; Noda, Chikara; Redhueil, Alban et al. DOI: 10.1007/s00134-023-07251-0
PMID: 35429504 Journal: NEUROPHARMACOLOGY Year: 2022 Reference: Neuropharmacology. 2022 Jul 1;212:109058. doi: 10.1016/j.neuropharm.2022.109058. Epub 2022 Apr 13. Impact factor: 5.251 Publication type: Paper in international publication Authors: Gonzalez-Sepulveda, Marta, Omar, Muhammad Yusof, Hamdon, Sally, Ma, Guofen, Rosell-Vilar, Santi, Raivio, Noora, Abass, Doaa, Martinez-Rivas, Anna, Vila, Miquel, Giraldo, Jesus et al. DOI: 10.1016/j.neuropharm.2022.109058
PMID: 34794916 Journal: Revista Espanola de Medicina Nuclear e Imagen Molecular Year: 2022 Reference: Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022 Jan-Feb;41(1):52-54. doi: 10.1016/j.remnie.2021.05.002. Epub 2021 Nov 16. Impact factor: 1.359 Publication type: Letter or abstract Authors: Carrillo-Villamizar, E, Cardozo-Saavedra, A, Lorenzo-Bosquet, C, Lucas Del Pozo, S, Martinez-Saez, E, Hernandez-Vara, J et al. DOI: 10.1016/j.remnie.2021.05.002
PMID: 33738725 Journal: ADVANCES IN THERAPY Year: 2021 Reference: Adv Ther. 2021 May;38(5):2054-2076. doi: 10.1007/s12325-021-01676-z. Epub 2021 Mar 18. Impact factor: Publication type: Review in international publication Authors: Abril-Gil, Mar; Albert-Bayo, Merce; Alonso-Cotoner, Carmen; Exposito, Elba; Gonzalez-Castro, Ana M; Lobo, Beatriz; Mall, John-P Ganda; Santos, Javier et al. DOI: 10.1007/s12325-021-01676-z
PMID: 33634751 Journal: Autophagy Year: 2021 Reference: Autophagy. 2021 Jan;17(1):1-382. doi: 10.1080/15548627.2020.1797280. Epub 2021 Feb 8. Impact factor: Publication type: Review in international publication Authors: Abdel-Aziz, Amal Kamal; Abdelfatah, Sara; Abdellatif, Mahmoud; Abdoli, Asghar; Abel, Steffen; Abeliovich, Hagai; Abildgaard, Marie H; Abudu, Yakubu Princely; Acevedo-Arozena, Abraham; Adamopoulos, Iannis E et al. DOI: 10.1080/15548627.2020.1797280
PMID: 33378073 Journal: REVISTA DE NEUROLOGIA Year: 2021 Reference: Rev Neurol. 2021 Jan 1;72(1):1-8. doi: 10.33588/rn.7201.2020181. Impact factor: Publication type: Paper in national publication Authors: Avila, A; Fernandez-Dorado, A; Gil-Villar, M P; Hernandez-Vara, J; Pastor, P; Planellas, L et al. DOI: 10.33588/rn.7201.2020181
PMID: 32183996 Journal: NEUROLOGIA Year: 2021 Reference: Neurologia. 2021 Jan - Feb;36(1):92-94. doi: 10.1016/j.nrl.2020.02.001. Epub 2020 Mar 14. Impact factor: Publication type: Letter or abstract Authors: Hernandez-Vara, J; Lucas-Del-Pozo, S; Moreno-Martinez, D; Tejero-Ambrosio, M et al. DOI: 10.1016/j.nrl.2020.02.001
PMID: 32786306 Journal: ACS Chemical Neuroscience Year: 2020 Reference: ACS Chem Neurosci. 2020 Sep 2;11(17):2679-2687. doi: 10.1021/acschemneuro.0c00336. Epub 2020 Aug 24. Impact factor: 4.486 Publication type: Paper in international publication Authors: Nicolau, Alba, Guillard-Sirieix, Camille, Xicoy, Helena, Kobayashi, Jumpei, Vila, Miquel, Compte, Joan, Penuelas, Nuria, Cuadros, Thais, Gonzalez-Sepulveda, Marta, Laguna, Ariadna et al. DOI: 10.1021/acschemneuro.0c00336
PMID: 32682292 Journal: PARKINSONISM & RELATED DISORDERS Year: 2020 Reference: Parkinsonism Relat Disord. 2020 Sep;78:31-35. doi: 10.1016/j.parkreldis.2020.06.037. Epub 2020 Jul 4. Impact factor: 3.926 Publication type: Paper in international publication Authors: Lucas-Del Pozo, S, Carter, S, Armengol-Bellapart, M, Castell-Conesa, J, Cuberas-Borros, G, Corominas-Roso, M, Lorenzo-Bosquet, C, Saez-Francas, N, Hernandez-Vara, J et al. DOI: 10.1016/j.parkreldis.2020.06.037
The initiative seeks to raise awareness of the disease and promote the well-being of those affected, while fostering empathy and scientific vocations among young people.
On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.
Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.
Vall d'Hebron Iniciativa per al Parkinson (VHIP) is a research project aimed at the development of biochemical markers for the early detection of Parkinson's disease. This study is carried out in people at high risk of having this disease, because they carry genetic mutations that predispose to the development of Parkinson's or because they present non-motor symptoms that manifest themselves years before motor symptoms.
